Dr. Michael Pesko Discusses New FDA Regulations of Electronic Nicotine Delivery Systems
The US Food and Drug Administration (FDA) recently issued new regulations for electronic nicotine delivery systems (ENDS) including vaporizers and e-cigarettes. The regulations will raise the purchasing age of ENDS to 18 years to align with cigarettes, require all ENDS manufacturers to submit chemical and manufacturing information for FDA review, which will result in new […]
NY State Moves to Remove Restrictions on HCV Drug Access by Private and Medicaid Insurers
According to a new report from the CDC, in 2014 one person died from hepatitis C (HCV) every 27 minutes, totaling 19,659 Americans in one year. The number of people dying from HCV surpassed the total number of deaths from 60 other infectious diseases combined, including HIV. Although lifesaving, the high cost of current treatments for […]
State Medicaid Spending on Sovaldi: Wide Variation in Spending and Utilization in 2014
With a price tag of $1,000 per pill and $84,000 for a 12-week course of Sovaldi (sofosbuvir), Gilead Sciences prompted widespread concern about whether its new treatment for hepatitis C (HCV) would bankrupt public and private payers. These concerns were particularly significant for state Medicaid programs, which face both limited state budgets and high HCV […]
Engage with CHERISH
Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.